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Abstract Apoptosis is a source of much research interest across many fields,
including developmental biology, immunology and oncology. As the exact pathways
of this process are identified, so too are potential avenues for therapeutic
application. Death receptors are important in inducing apoptosis and together with
their ligands have become a source of attention as potential therapeutic agents. This
review provides an introduction to the role of death receptors in apoptosis, together
with a look at possible areas where this information may be applied therapeutically.
ª 2005 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Apoptosis, or programmed cell death, is the
ultimate fate of many of our cells. Apoptosis is
distinct from necrosis in that the former is a regu-
lated active process, while the latter is not. From
embryogenesis and beyond, apoptosis has a crucial
role in maintaining normal cell turnover and in
preventing the propagation of damaged or danger-
ous cells. The importance of apoptosis is evident by
the array of conditions caused by disorders in
apoptosis; certain forms of cancer, autoimmune
disease, and neurodegenerative diseases where,
rather than a failure in apoptosis, there is an excess
of it.1 Aside from programmed cell death, cells may
also commit suicide in response to external noxious
stimuli that result in damage.
* Corresponding author.
E-mail address: rajesh357@yahoo.com (R. Kumar).1743-9191/$ - see front matter ª 2005 Surgical Associates Ltd. P
doi:10.1016/j.ijsu.2005.05.002Mechanisms of apoptosis
Caspases (cysteine-dependent aspartate-specific
proteases) are the means by which apoptosis is
effected (caspase-independent apoptosis is de-
scribed, but will not be discussed here). Two major
mechanisms exist by which caspases are activated:
the ‘intrinsic’ and ‘extrinsic’ pathways.2 The in-
trinsic pathway is activated by mitochondrial
disruption with subsequent cytochrome c release.
Initiators of this pathway include UV irradiation
and cytotoxic drugs.1 An ‘apoptosome’ is formed
by the interaction of cytochrome c, Apaf-1, d-ATP/
ATP and procaspase-9 with subsequent initiation of
the caspase cascade.3,4 This pathway is regulated
by members of the Bcl-2 family.5e7
The extrinsic pathway involves the binding of
ligands to cell surface ‘death receptors’ (DR) whichublished by Elsevier Ltd. All rights reserved.
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receptors are part of the tumour necrosis factor
(TNF) gene superfamily and provide a rapid and
efficient route to apoptosis. The characteristics of
death receptors are cysteine-rich extracellular
domains and an intracellular cytoplasmic sequence
known as the ‘death domain’.9,10 The death re-
ceptors best described to date are listed in Table 1
together with their various synonyms. In bold are
the terms that will be used throughout this article.
The molecular pathways by which TNFR1 and
Fas effect apoptosis have been best characterized,
with the role of TRAIL receiving greater attention
more recently and so these will be considered in
further detail later. Fundamentally, the death
receptors share a similar means by which the
caspase enzymatic cascade is activated and this
is discussed below.
Death receptors are type I transmembrane
proteins and it is their intracytoplasmic death
domain (DD) component that is essential for signal
transduction and apoptosis to occur.10,25 Upon
binding its cognate ligand, Fas Ligand, the Fas
receptor undergoes trimerisation, thus encouraging
the binding of the adaptor protein FADD (Fas-
associated DD protein, alternatively known as me-
diator of receptor-induced toxicity (MORT1)).26,27
FADD not only has a DD, but also another domain
known as the death effector domain (DED) which
allows it to bind the DED of procaspase-8.27 This
aggregation of FADD and the initiator procaspase-8
is known as a death-inducing signaling complex
(DISC).28 Further recruitment of multiple procas-
pase-8 zymogen molecules results in cross-activa-
tion and autocatalysis with active caspase-8
generated and released into the cytoplasm.29e31
The other death receptors activate caspase-8 in
a similar fashion with TRAIL-R1 and TRAIL-R2 di-
rectly binding FADD, although the TNFeTNFR1
complex utilises an extra intermediary. Following
binding of TNF to TNFR1 and trimerisation, the
adaptor molecule TRADD (TNFR-associated death
Table 1 Summary of the best characterized death
receptors and their cognate ligand
Activating
ligand
Death receptor
TNF TNFR1/DR1/CD120a/p5511
FasL/CD95L Fas/CD95/Apo1/DR212,13
Apo3L/TWEAK DR3/Apo3/WSL-1/TRAMP/LARD13e17
TRAIL/Apo2L TRAIL-R1/DR418
TRAIL-R2/DR5/Apo-2/TRAILCK2/
KILLER19e23
TRADD DR624domain) is recruited to facilitate binding of FADD to
the receptor complex32 with subsequent recruit-
ment of procaspase-8 as before. A further differ-
ence between Fas- and TNFR1-mediated signaling is
the ability of TRADD to recruit secondary adaptors
such as RIP (a serineethreonine kinase receptor-
interacting protein) and TRAF2 (TNF receptor-asso-
ciated factor 2).33 These, respectively, activate
the NF-kB and JNK/AP-1 survival pathways,33 i.e.
can negate the apoptotic signal and ensure cell
survival. A similarity between Fas and TRAIL sys-
tems is their ability to activate both the extrinsic
and intrinsic apoptosis pathways. This occurs from
the cleavage by procaspase-8 of themolecule Bid (a
pro-death member of the Bcl-2 gene family).34e38
The active part of the cleaved Bid translocates into
mitochondria, binds Bax or Bak (pro-apoptotic
members of the Bcl-2 family39,40) with resultant
mitochondrial fragmentation, cytochrome c re-
lease and apoptosome formation as before.
Bid, therefore, acts as a bridge between the
extrinsic and intrinsic pathways. In certain cells
(known as type 1) activation of caspase-8 is
sufficient to enable apoptosis to occur through its
downstream activation of effector caspases-3
and -6. Other cells (termed type II) are less able
to form the DISC and the extrinsic pathway
requires amplification via the mitochondrial path-
way, and it is here the role of Bid as a link between
the pathways is relevant.41
Clearly, uncontrolled death receptor activation
and apoptosis would be disastrous for an organism.
To prevent this, signaling of these receptors is
regulated in several ways, including anti-apoptotic
proteins within cells, and the activation of tran-
scription factors (Fig. 1).
Death and decoy receptors
Control of activation of any receptor may be
restricted by restricting the expression of the
receptor or its respective ligand. TNFR1, Fas,
TRAIL-R1 and TRAIL-R2 are expressed in a wide
variety of tissues while the tissue distribution of
TNF and FasL is more limited: TNF is expressed
mainly by activated T cells and macrophages, and
FasL by cytotoxic T cells, NK cells and antigen
presenting cells. By contrast TRAIL is constitutively
expressed in a wide range of human
cells.8,11,17,35,42e46
TNF, FasL and TRAIL all exist as both soluble and
membrane-bound forms. The relative functions of
each are still being elucidated. Cleavage of
the membrane-bound forms of TNF and FasL
by metalloproteinases to the soluble form may
270 R. Kumar et al.Figure 1 Simplified overview of events following death receptor activation.represent a method of control since the soluble
forms are less effective at initiating apoptosis.47
The wide range of cells on which both TRAIL and
its death receptors are expressed (by contrast to
TNF and FasL) implies that cells must employ
mechanisms to protect themselves from unwanted
self-destruction or death from neighbouring cells.
One mechanism is the use of decoy receptors.
DcR1 and DcR2 are cell surface receptors which
bind TRAIL with high affinity, but are incapable of
conveying an appropriate intracellular signal to
induce apoptosis. DcR1 and DcR2 are structurally
similar to TRAIL-R1 and TRAIL-R2, respectively, but
the former has no cytoplasmic tail,18,21,48e51 while
the latter has only a truncated, ineffective
DD.48,52,53 The differential expression of decoy
and death receptors which competitively bind
TRAIL may offer an explanation of the observation
that TRAIL ligation is fatal to some cells and not
others; specifically, most normal cells compared to
many cancer cells are resistant to TRAIL-induced
death. However, this cannot be the sole regulatory
mechanism as many tumour lines remain vulnera-
ble to TRAIL-induced apoptosis while expressing
high levels of decoy receptor.54 Fas too has a decoy
receptor, DcR3,55 whose overexpression inhibits
Fas-induced apoptosis.
The regulation of death
Moving to regulatory mechanisms within the
cell, the silencer of death domains (SODD) is aninhibitory protein acting on DDs. It acts on the DD
of TNFR1 and DR3 to prevent unwarranted aggre-
gation of DDs leading to ligand-independent apo-
ptosis.56 Similar proteins may exist for the other
death receptors.
c-FLIP is the cellular inhibitor of caspase-8 that
contains two DEDs but lacks an active site and can
bind Fas or TRAIL-DISCs to prevent activation of
caspase-8 or -10.57
The Bcl-2 family of proteins control the release
of cytochrome c,58 which itself is released upon
mitochondrial disruption and occurs with the cleav-
age of Bid. Bid, Bax, and Bak are members of the
Bcl-2 family and are pro-apoptotic, while Bcl-2 and
Bcl-XL inhibit cytochrome c release and are anti-
apoptotic. It seems that anti-apoptotic molecules
such as Bcl-XL compete for binding with the
activated form of Bid, and upon doing so prevent
it activating Bax or Bak, thereby avoiding the
mitochondrial release of cytochrome c.59 The out-
come of this competition between pro-apoptotic
and anti-apoptotic molecules determines whether
the signal for cell death is successful.
Caspases are initially synthesized in an inactive
(procaspase) form and are activated by other
caspases, or upon binding to the DISC, or apopto-
some. Caspase regulation is also achieved by their
interaction with inhibitors-of-apoptosis proteins
(IAPs).60 There are several human homologues e
cIAP1, cIAP2, XIAP, NIAP, SURVIVIN and BRUCE.
They act by binding to and inhibiting the activity of
effector caspases-3, -6 and -7.61 XIAP prevents
activation of procaspase-9 by binding it while at
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of multiple effector caspases. The regulatory
ability of IAPs is countered by the release of
Smac/DIABLO from mitochondria, which seques-
ters IAPs to promote caspase activation.64
NF-kB is a transcription factor, the activation of
which generates pro-survival signals.65 It promotes
the expression of c-FLIP, Bcl-XL, XIAP, TRAF1 and
TRAF2, whose anti-apoptotic roles have been men-
tioned above. There appears to be a differential
ability in the capacity of the various death receptor
ligands to induce NF-kB, with FasL being unable to
do so, and TRAIL doing so to a lesser extent than
TNF (perhaps explaining the stronger death-inducing
capability of FasL compared to TNF).66
Pro-survival vs pro-death
Binding of ligands to cell surface death receptors
and caspase activation is moderated by several
anti-apoptotic mechanisms, some of which have
already been described. As we have said, this is
clearly necessary to circumvent widespread cell
death within an organism, but apoptosis too is
physiologically crucial, and failure here results in
uncontrolled growth, neoplasia and immune dis-
turbance. ‘Constructive destruction’ then is
achieved by tipping the balance with the induced
expression of death receptors and by caspase-
mediated proteolysis of anti-apoptotic molecules.
Caspases target the very molecules which mediate
NF-kB activation as substrates,67 together with
inhibiting NF-kB itself and its products. In addition,
both Bcl-2 and Bcl-XL and IAPs are substrates for
caspases.60,68
By understanding the mechanisms of apoptosis
and the exact role of factors that either promote
or antagonise this outcome, we may begin to
influence this process in pathological states.
Next, we will consider the physiologic role of
death receptors and apoptosis in the immune
system and in tumour surveillance before consid-
ering the therapeutic potential of these vital
molecules.
Death receptors and ligands in the
development of normal function of
the immune system
Lymphocyte development, clonal expansion in re-
sponse to a stimulus with subsequent control to
maintain homeostasis, and appropriate receptor
repertoire development all rely on death receptor-
induced cell death. Immature T cells mature
within the thymus and undergo T cell antigenreceptor selection where death receptors are
thought to be involved in inducing apoptosis in
those cells which do not undergo appropriate T cell
antigen receptor rearrangement.69 Fas is thought
to have a role in the peripheral deletion of T cells
occurring during T cell development.70,71 Following
an immune response resulting in clonal expansion
of antigen-specific T cells there needs to be a cull
in the number of these cells to previous levels, and
this occurs by ‘activation-induced cell death’
(AICD). AICD is mediated by FaseFasL and TNFe
TNFR interactions.70,72e76
As mentioned before, FasL is expressed on
activated T cells and NK cells where its expression
allows these cells to function within the immune
system to eliminate infected cells, cancer cells
and attack transplanted tissues which carry the Fas
receptor.35 FasL is also expressed within certain
‘immune privileged’ sites such as the eye, Sertoli
cells of the testes, brain and placenta.77,78
Immune privileged sites are those that do not
initiate an immune response when antigen is
introduced. This is essential in a structure where
inflammatory reactions could compromise the in-
tegrity and function of an organ. In the eye,
several mechanisms to explain immune privilege
have been proposed, including the ‘‘blood-ocular
barrier’’ and direct lymphatic drainage. In addi-
tion, the cornea constitutively expresses function-
ally active FasL.79 The FaseFasL system can then
cause apoptosis in invading Fas-positive inflamma-
tory cells,80 thus reducing the immune response.
Indeed, it has been shown that a lack of FasL leads
to damage during an immune response.80,81
FasL expression e role in graft
protection
The association of FasL with immune privilege gave
rise to the hope that the artificial expression of
FasL on transplanted tissue might act as a local
immunosuppressant, since invading activated lym-
phocytes express Fas, and would thus undergo
apoptosis when they came into contact with the
graft. However, some studies, but not all, demon-
strated that islet cell grafts expressing FasL are
rapidly destroyed, not by the classical lymphocyte-
mediated rejection pathway, but rather by granu-
locytic destruction of the grafted cells.82e84
Several groups have worked with the FasL mole-
cule to establish if it could play a role in modifying
the immune response to allografts. Particularly
encouraging was work done on the eye.
In a corneal model of transplantation, FasL-
positive grafts were accepted at a rate of 45e50%,
272 R. Kumar et al.whereas FasL-negative grafts were rejected at
around 100%.85,86 However, experiments in organs
other than the eye produced conflicting data,
suggesting that FasL can be either immunoprotec-
tive or immunodestructive.11,23,41
There is some evidence that FasL is upregulated
on non-haematopoietic cells in the context of in-
flammation87,88 and work in our laboratory has
investigated this further to show that it is upregu-
lated on non-haematopoietic cells during the re-
jection of allogeneic skin. We have demonstrated
that skin transplanted from FasL-defective mice is
rejected at a more rapid rate than wild type skin. In
part, this reflects the differential susceptibility of
FasL-deficient andnormal skin to theeffector armof
the immune response. However, it is now clear that
FasL’s effects are not limited to the effector arm; it
appears that the nature of the immune response
generated if a graft has defective FasL is more
vigorous than if FasL is present. Using bone marrow
chimeras, in which skin is transplanted from FasL-
defective mice which have been reconstituted with
wild type marrow, or from wild type animals whose
marrow has been reconstituted from a FasL-
defective source, it appears that this effect on the
afferent limbof the immune response ismediatedby
the presence of FasL on skin haematopoietic cells.
Current data suggest a potential future use for
membrane-bound FasL in graft protection,89
though its effects have still to be fully elucidated.
One model developed by Swenson et al.,90 used
a viral gene transfer method to induce expression
in allotransplanted rat kidneys. The successfully
transfected kidneys showed a significantly pro-
longed survival time.
However, it is also worth mentioning the other
side of the story, the role of FasL-expressing
allospecific cytotoxic T-lymphocytes, which may
bind to Fas expressed on transplanted organs,
leading to apoptosis of cells within these tissues.91
This leads to the suggestion that the down-regula-
tion of FasL and TNF-alpha in allografts rendered
tolerant by donor-specific transfusion plays a role
in acute allograft rejection.92 Other work has
concluded that Fas-mediated cytotoxicity is not
required for the rejection of murine nonvascular-
ised heterotopic cardiac allografts.93,94
Death receptors and ligands in tumour
surveillance and anticancer therapy
Murine experiments have demonstrated TRAIL ex-
pression on liver NK cells (NK cells playing an
important role in the control of tumour spread),
but not other NK cells, T cells or conventionalT cells.95 TRAIL, perforin and FasL together are
responsible for NK cell-mediated inhibition of liver
metastasis.95 Blocking expression of either TRAIL or
FasL with monoclonal antibodies prevents liver NK
cell cytotoxicity in vitro, and increases hepatic
metastases of several tumour cell lines.95 Crucial to
expression of TRAIL and FasL on NK cells is in-
terferon-g (IFN-g).96 Experiments in TRAIL-defi-
cient mice have further substantiated the
important role of TRAIL against tumour develop-
ment and metastasis.97
Interferons are cytokines with important anti-
tumour roles and it seems one of theways they carry
out their role is by using TRAIL as a mediator. IFN-g
induces TRAIL expression on cytotoxic T cells98 and
TRAIL expression is reduced on NK cells in mice
deficient in IFN-g.95 CD4C T cell-dependent intra-
ocular rejection of a particular tumour cell line does
not require CD8C T cells, B cells, TNF, perforin,
FasL, or NK cells, but is mediated by TRAIL-induced
apoptosis and susceptibility to this killing is en-
hanced by IFN-g.99 Melanoma cells resistant to FasL
have been shown to be susceptible to CD4C T cell
killing mediated by TRAIL-induced apoptosis.100
Human cancers develop ways of evading host
defence mechanisms and conventional therapies,
e.g. by the loss of the p53 tumour suppressor
gene.101 p53 mainly initiates apoptosis via the
intrinsic pathway and its intact function is required
for many DNA-damaging drugs to be effective.
Inactivation of p53 can lead to resistance.
Death receptors offer away around this by initiating
apoptosis independent of p53, especially useful in
cells already resistant to chemo- and radiotherapy.
The successful therapeutic administration of
death receptor ligands or antibodies to these
receptors in vivo, however, will depend on a dif-
ferential effect on cancer cells compared to
normal cells. Administering TNF causes a serious
inflammatory response and systemic FasL causes
hepatic apoptosis. TRAIL, however, has become an
anticancer agent with promising potential. TRAIL
appears to demonstrate the required ability of
killing tumour cells while leaving normal cells
alone,102,103 and in addition induces apoptosis in
a number of cancer cell lines regardless of their
p53 status.104 In addition, animal experiments
have failed to show any serious adverse systemic
effects of TRAIL administration.102,103
The exact mechanisms for the resistance of
normal cells to TRAIL have yet to be fully eluci-
dated, but the previously mentioned decoy recep-
tors may play a part. The expression of DcR1
and DcR2 may confer protection against TRAIL
and their overexpression is a possible mechanism
for tumour evasion, with DcR1 increased in
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have also been implicated in protecting normal
cells106 and overexpression in certain tumours and
in melanoma results in TRAIL resistance.107
Given the host of anti-apoptotic mechanisms in
place described earlier, there are a number of
potential avenues for cancer cells to evade death
and proliferate. Aside from FLIP, Bax is another
target for inactivation often found in cancers with
deficient DNA mismatch repair.108,109 Upregulation
of Bcl-XL is another method.
110 Remembering that
NF-kB orchestrates induction of proteins such as
FLIP and Bcl-XL, it is not unreasonable to expect
TRAIL resistance to be found in tumours expressing
high levels of NF-kB.111
Understanding such mechanisms of resistance
also provides the possibility for sensitizing TRAIL-
resistant cells, perhaps with NF-kB inhibitors,112 by
reducing FLIP expression, or with the use of
chemotherapeutic agents to upregulate p53,
TRAIL-R2 and Bak.113 Such combinations may pro-
vide a synergistic effect on killing cancer cells.
Other strategies under investigation include tar-
geting Bcl-2,114,115 XIAP,116 Smac117 and increasing
APAF-1 expression.118
Promising results have been seen with human
TRAIL-R1 monoclonal antibody (HGS-ETR1) experi-
ments.119 In vitro treatment of tumour cell lines
enhanced the cytotoxic activity of chemothera-
peutic agents, even where HGS-TR1 alone was not
effective. Corresponding results were found in vivo
with tumour regression or repression with HGS-TR1
treatment. Combination treatment with chemo-
therapy again produced enhanced anti-tumour
activity.119 Such potential against a broad range
of malignancies is under further investigation and
Phase II clinical trials of HGS-TR1 are underway in
patients with non-small cell lung cancer, colorec-
tal cancer and non-Hodgkin’s lymphoma.
Aside from use of the recombinant ligand
and agonist antibodies to the TRAIL death recep-
tors, gene therapy may offer another treatment
modality. High levels of transgene expression using
an adenoviral vector expressing TRAIL and causing
apoptosis in a variety of breast cancer cell lines
have been demonstrated.120 Gene therapy remains
a novel technique and its application in this form
may be restricted to local therapy.121,122
Bone metabolism, fracture and wound
healing
Bone remodeling requires the resorptive actions of
osteoclasts and the laying down of bone matrix by
osteoblasts. Here too members of the TNF ligandfamily have a significant role to play. These in-
clude receptor activator of NF-kB ligand (RANKL),
the receptor RANK and the soluble decoy receptor
osteoprotogerin (OPG).
Animals injected with OPG, or transgenic mice
overexpressing OPG are found to have increased
bone mass123,124 while OPG knockout mice show
severe osteoporosis.125 OPG, thus, appears to be
important in inhibiting osteoclast bone resorption.
Within bone, RANKL serves to stimulate mature
osteoclast activity126 and inhibit osteoclast apo-
ptosis.127
Osteoclasts and osteoblasts arise from separate
cell lineages, the former from haematopoietic
precursors and the latter from mesenchymal stem
cells. It is the interaction between RANKL found on
osteoblasts and its receptor RANK, expressed on
osteoclast precursors, that is essential for osteo-
clastogenesis. Together with OPG, RANKL and
RANK play a crucial role in bone metabolism and
are also involved in fracture healing.
In a mouse tibia fracture model, RANKL expres-
sion was strongly induced throughout the period of
fracture healing, but was almost undetectable in
non-fractured bone.128 While OPG shows constitu-
tive expression even in unfractured bone, it too is
upregulated during fracture repair. Aside from
fracture healing, an area where such knowledge
may be applied is in structural musculoskeletal
grafts. Bone grafts can often be harvested from
allogeneic cadaveric donors, however, vascular-
ised fresh autologous grafts are significantly better
to graft, with improved healing and remodel-
ing.129,130 Allografts are lacking several factors
important in angiogenesis and bone remodeling
and RANKL has recently been demonstrated to be
necessary for complete autograft healing.131 Fur-
thermore, recombinant adeno-associated virus, as
a vector for RANKL, when applied to the surface of
allografts showed significant remodeling and vas-
cularisation, leading to a new bone collar around
the graft.131
Unsurprisingly, given the inflammatory response
that occurs with injury and the necessity for
resolution of this response, apoptosis is of impor-
tance in wound healing too.132,133 One of the
factors mediating apoptosis and controlling the
inflammatory response is transforming growth
factor b (TGFb).134 The pro-apoptotic effects of
TGFb appear to involve caspases and its effects
may be inhibited by Bcl-XL.
135,136 TGFb is under
further investigation because of its differential
expression in embryonic tissue compared to
adult tissue. Skin wounds early in gestation on
a mammalian fetus heal without scarring and the
growth factor profile here is different to the adult
274 R. Kumar et al.situation. With embryonic wounds there are low
levels of TGFb1 and TGFb2, low levels of platelet-
derived growth factor (PDGF) and high levels of
TGFb3.137 Therapeutic manipulation of wounds in
animals by neutralizing PDGF, TGFb1 and TGFb2,
and adding exogenous TGFb3 results in scar-free
healing.137 Pharmaceutical molecules based on
these experiments have entered trials on wound
healing in humans.137
Conclusion
The dynamic balance between death receptors
and anti-apoptotic mechanisms is vital to regulat-
ed cell death, disturbance of which can be severely
detrimental to an organism. As the exact molecu-
lar events are delineated and the players in this
process identified, so too potential therapeutic
avenues open up. The manipulation of death
receptors and their ligands has possible future
implications in a variety of areas, including the
treatment of cancers and inflammatory disorders,
bone and soft tissue healing and in transplant
rejection.
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